Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Aug
09
Today In Oncology
Oral Nicotinamide May Offer Cost-Effective Prevention of Keratinocyte Carcinoma
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Durvalumab Plus BCG Improves Outcomes in High-Risk Non–Muscle-Invasive Bladder Cancer
AMH Levels May Predict Adjuvant Chemotherapy Benefit in Premenopausal Women With Breast Cancer
WHO Calls for Action in New Status Report on Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo